Immunotherapy advancements: transforming cancer treatment

29 July 2024


In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.

This webinar will offer a comprehensive exploration of the current landscape of immunotherapy research. Our esteemed panel will provide detailed insights into recent developments, including both successes and obstacles encountered within the field. We will examine the evolving methodologies and emerging technologies shaping immunotherapy, while also considering the challenges that researchers face. Additionally, we will discuss potential future directions for the field, highlighting opportunities for further advancement.

Our panellists will highlight the expanding spectrum of indications for immunotherapy and its potential in diverse cancer scenarios. Additionally, we’ll tackle the significant challenge of overcoming resistance to immunotherapy, discussing strategies like combination therapies, biomarker-guided approaches, and innovative treatment methods.

Furthermore, our panellists will discuss the concept of tailored immunotherapy, which aims to customise treatment strategies based on individual patient characteristics including tumour genetics and immune profiles, and its implications for patient care.

Key learning points:

Expanding indications: immunotherapy has demonstrated remarkable efficacy across various cancer types, including melanoma, lung cancer, and haematological malignancies. We’ll discuss the expanding indications for immunotherapy and its potential applications in diverse cancer settings.
Overcoming resistance: despite its successes, resistance to immunotherapy remains a significant challenge. We’ll explore strategies to overcome resistance mechanisms, including combination therapies, biomarker-driven approaches, and novel treatment modalities.
Precision immunotherapy: personalised or precision immunotherapy aims to tailor treatment approaches based on individual patient characteristics, including tumour genetics and immune profiles. We’ll explore into the latest advancements in precision immunotherapy and its implications for patient care.
Future directions and challenges: looking ahead, we’ll discuss emerging trends, ongoing pre-clinical research, and the evolving landscape of immunotherapy research. Additionally, we’ll address key challenges such as immune-related toxicities, biomarker identification, and access to innovative therapies.

Join us as we navigate through the latest advancements in immunotherapy research in a balanced and informative discussion.

Register to join this webinar for free



Steve Worland, PhD, President & Chief Executive Officer of eFFECTOR Therapeutics

Dr Steve Worland has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2012. Previously, Dr. Worland served as Chief Executive Officer of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from August 2007 until its acquisition by Roche Holding AG in 2011. Prior to his appointment as Chief Executive Officer of Anadys Pharmaceuticals, Dr. Worland served as its Chief Scientific Officer and President, Pharmaceuticals. Prior to Anadys Pharmaceuticals, Inc., Dr. Worland was Vice President and Head of Antiviral Research at Pfizer Inc. and Vice President at WarnerLambert Co., where he was responsible for worldwide anti-infectives strategy. Dr. Worland has served on the board of directors of Tracon Pharmaceuticals, Inc., a biopharmaceutical company, since February 2015. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University and completed a Ph.D. in Chemistry at the University of California, Berkeley. He received his B.S. with Highest Honors in Biological Chemistry from the University of Michigan.


Keir Loiacono, Esq., Chief Executive Officer of BlueSphere Bio

Mr Loiacono brings nearly 20 year of transactional experience from the biotech, pharmaceutical and medtech industries. A patent lawyer by training, Mr Loiacono represented companies of various sizes in all stages of transactions, including licensing and M & A. As a seasoned life sciences executive in the oncology sector, he has extensive experience raising capital in the public capital market space and closed numerous deals including licenses, clinical collaborations and strategic transactions with significant upfront payments. Prior to being appointed Chief Executive Officer, Mr Loiacono served as Chief Business Officer for BlueSphere.

Prior to joining BlueSphere, Mr Loiacono was the Vice President of Business Development and General Counsel of OncoSec Medical Inc., a public, clinical-stage oncology company. Earlier in his career, he worked as a senior director for Advaxis, Inc., a late stage, publicly traded, immuno-oncology company focused on developing, manufacturing and commercializing cancer vaccines, where he oversaw various legal, transaction and compliance functions. Before Advaxis, Mr Loiacono was an IP attorney with Lerner David Littenberg Krumholz & Mentlik, where he focused on transactions and building patent portfolios. For nearly a decade before this role, he held various commercial roles with OraPharma, a specialty pharmaceutical company that was purchased by Johnson & Johnson. He also serves on the Board of Directors for EpiAxis Therapuetics, an early-stage drug discovery company focusing on the LSD-1 pathway.


Philipp Spycher, PhD, Co-Founder & Chief Scientific Officer of Araris Biotech

As the inventor of the Araris ADC Technology, Philipp has a profound background in Bioconjugation and ADCs. He was the founding CEO since the inception of Araris in 2019 securing $40M in financing from Swiss, UK, US and Korean investors and $2.5M non-dilutive financing from the Swiss Accelerator Grant (5% funding rate). He positioned Araris to shift the paradigm in how to think about developing targeted cancer therapies and since October 2023, he transitioned to become its CSO. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris ADC Technology. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering.


Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

When will the webinar take place?
The webinar will take place live on 29th July at 15:00 BST

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.

Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.